ReShape Lifesciences Inc (RSLS)

Name: ReShape Lifesciences Inc Financial Statements
Creator: Quarter Results

Healthcare | Medical Devices

Latest reporting period: 2024-12-31

Latest Quarter

2024-12-31

Revenue

$1.8M

Net Income

-$1.8M

Operating Margin

-35.6%

Free Cash Flow

-$4.4M

Debt / Assets

105.3%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for ReShape Lifesciences Inc (RSLS).
Income Statement (Quarterly)	2024-12-31	2024-09-30	2024-06-30	2024-03-31
Revenue	1,805,000	2,292,000	1,965,000	1,944,000
Cost of Revenue	486,000	853,000	831,000	779,000
Gross Profit	1,319,000	1,439,000	1,134,000	1,165,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	1,440,000	2,801,000	2,789,000	2,891,000
Operating Expenses	1,962,000	3,200,000	3,188,000	3,375,000
Operating Income	-643,000	-1,761,000	-2,054,000	-2,210,000
Interest Expense	0	0	0	0
Income Before Tax	-1,756,000	-1,575,000	-1,580,000	-2,179,000
Income Tax Expense	5,000	6,000	15,000	14,000
Net Income	-1,761,000	-1,581,000	-1,595,000	-2,193,000
Per Share
EPS	-1.63	-3.11	-3.67	-5.42
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for ReShape Lifesciences Inc (RSLS).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	319,714	8,006,000	8,678,000	11,240,000	13,600,000
Cost of Revenue	112,928	2,949,000	3,130,000	4,438,000	5,252,000
Gross Profit	206,786	5,057,000	5,548,000	6,802,000	8,348,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	2,365,565	9,922,000	17,872,000	31,343,000	33,575,000
Operating Expenses	2,953,823	11,725,000	20,187,000	33,880,000	36,097,000
Operating Income	-2,747,037	-6,668,000	-14,639,000	-27,078,000	-56,501,000
Interest Expense	146,641	0	0	113,000	832,000
Income Before Tax	-10,477,713	-7,091,000	-11,335,000	-46,594,000	-62,039,000
Income Tax Expense	0	39,000	52,000	-380,000	-106,000
Net Income	-10,262,007	-7,130,000	-11,387,000	-46,214,000	-61,933,000
Per Share
EPS	-4.75	-13.83	-110.88	-108.90	-250.16
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for ReShape Lifesciences Inc (RSLS).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	693,000	4,559,000	3,855,000	22,765,000
Short Term Investments	0	0	0	0
Net Receivables	987,000	1,659,000	2,180,000	2,815,000
Inventory	2,460,000	3,741,000	3,611,000	3,003,000
Total Current Assets	4,588,000	10,296,000	9,911,000	30,255,000
Property Plant Equipment	154,000	310,000	869,000	1,720,000
Goodwill and Intangibles	0	0	260,000	20,827,000
Total Assets	4,793,000	10,727,000	11,142,000	54,258,000
Liabilities
Account Payables	2,208,000	1,689,000	1,926,000	3,468,000
Short Term Debt	926,000	111,000	171,000	279,000
Total Current Liabilities	4,985,000	3,777,000	7,481,000	7,331,000
Long Term Debt	41,000	151,000	0	0
Total Liabilities	5,046,000	4,064,000	7,481,000	8,186,000
Shareholders Equity
Retained Earnings	-642,704,000	-635,574,000	-624,187,000	-576,760,000
Total Shareholders Equity	-253,000	6,663,000	3,661,000	46,072,000

Balance sheet annual history for ReShape Lifesciences Inc (RSLS).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets
Cash and Cash Equivalents	693,000	4,559,000	3,855,000	22,765,000	2,957,000
Short Term Investments	0	0	0	0	0
Net Receivables	987,000	1,659,000	2,180,000	2,815,000	2,620,000
Inventory	2,460,000	3,741,000	3,611,000	3,003,000	2,244,000
Total Current Assets	4,588,000	10,296,000	9,911,000	30,255,000	8,944,000
Property Plant Equipment	154,000	310,000	869,000	1,720,000	1,049,000
Goodwill and Intangibles	0	0	260,000	20,827,000	27,022,000
Total Assets	4,793,000	10,727,000	11,142,000	54,258,000	37,061,000
Liabilities
Account Payables	2,208,000	1,689,000	1,926,000	3,468,000	3,655,000
Short Term Debt	926,000	111,000	171,000	279,000	314,000
Total Current Liabilities	4,985,000	3,777,000	7,481,000	7,331,000	11,605,000
Long Term Debt	41,000	151,000	0	0	163,000
Total Liabilities	5,046,000	4,064,000	7,481,000	8,186,000	22,573,000
Shareholders Equity
Retained Earnings	-642,704,000	-635,574,000	-624,187,000	-576,760,000	-514,827,000
Total Shareholders Equity	-253,000	6,663,000	3,661,000	46,072,000	14,488,000

Cash flow quarterly history for ReShape Lifesciences Inc (RSLS).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-7,130,000	-11,387,000	-46,214,000	-61,933,000
Depreciation & Amortization	22,000	154,000	2,153,000	1,971,000
Stock Based Compensation	184,000	767,000	2,087,000	12,752,000
Change in Working Capital	2,291,000	-4,134,000	709,000	-2,741,000
Operating Cash Flow	-4,427,000	-16,960,000	-21,902,000	-15,375,000
Investing Activities
Capital Expenditure	0	-43,000	-131,000	-352,000
Investments	0	-43,000	-131,000	0
Investing Cash Flow	0	-10,000	-92,000	1,855,000
Financing Activities
Debt Repayment	653,000	0	0	-10,500,000
Common Stock Issued/Repurchased	24,000	17,574,000	639,000	0
Dividends Paid	0	0	0	0
Financing Cash Flow	677,000	17,574,000	3,130,000	33,299,000
Summary
Free Cash Flow	-4,427,000	-17,003,000	-22,033,000	-15,727,000
Net Change in Cash	-3,766,000	604,000	-18,860,000	19,808,000

Cash flow annual history for ReShape Lifesciences Inc (RSLS).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Operating Activities
Net Income	-7,130,000	-11,387,000	-46,214,000	-61,933,000	-21,630,000
Depreciation & Amortization	22,000	154,000	2,153,000	1,971,000	1,667,000
Stock Based Compensation	184,000	767,000	2,087,000	12,752,000	1,323,000
Change in Working Capital	2,291,000	-4,134,000	709,000	-2,741,000	6,000
Operating Cash Flow	-4,427,000	-16,960,000	-21,902,000	-15,375,000	-8,550,000
Investing Activities
Capital Expenditure	0	-43,000	-131,000	-352,000	-390,000
Investments	0	-43,000	-131,000	0	0
Investing Cash Flow	0	-10,000	-92,000	1,855,000	-2,390,000
Financing Activities
Debt Repayment	653,000	0	0	-10,500,000	0
Common Stock Issued/Repurchased	24,000	17,574,000	639,000	0	0
Dividends Paid	0	0	0	0	0
Financing Cash Flow	677,000	17,574,000	3,130,000	33,299,000	11,075,000
Summary
Free Cash Flow	-4,427,000	-17,003,000	-22,033,000	-15,727,000	-8,940,000
Net Change in Cash	-3,766,000	604,000	-18,860,000	19,808,000	22,000